http://www.cancer.ucla.edu// This is the syndication feed for UCLA's Jonsson Comprehensive Cancer CenterSat, 18 May 2013 20:27:17 -0700Celeste Mills is the first cancer patient in the country to try the drug treatment Kadcyla. After fighting metastatic breast cancer for 14 years, Mills completed a clinical trial at UCLA's Jonsson Comprehensive Cancer Center. In this two-part Hallmark video interview, Mills and UCLA researcher...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=638Wed, 01 May 2013 11:30:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=638Joe Cohen and Dr. Judith GassonMore than $780,000 was raised at the Jonsson Cancer Center Foundation’s 18th annual signature fundraising event, "Taste for a Cure," held April 26, 2013 at the Beverly Wilshire Hotel. The money will support highest priority research at UCLA’s Jonsson...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=636Mon, 29 Apr 2013 16:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=636UCLA researchers led by Dr. Patricia Ganz, director of cancer prevention and control research at the Jonsson Comprehensive Cancer Center, professor of health policy and management at the Fielding School of Public Health and professor of medicine at the David Geffen School of Medicine, have published...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=634Wed, 24 Apr 2013 09:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=634Anne Coscarelli, Ph.D., director of the Simms/Mann–UCLA Center for Integrative Oncology and member of UCLA’s Jonsson Comprehensive Cancer Center (JCCC) was awarded the Outstanding Clinical Care Award for 2013 by the American Psychosocial Oncology Society in February. She is the founding director of...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=632Mon, 15 Apr 2013 15:30:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=632Dr. Dennis Slamon Dr. Richard FinnAn experimental drug investigated for the treatment of advanced breast cancer by researchers from the Revlon/UCLA Women’s Cancer Research Program at UCLA’s Jonsson Comprehensive Cancer Center (JCCC) today received “Breakthrough Therapy” designation by...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=630Thu, 11 Apr 2013 12:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=630Dr. Edward Garon, M.D., of UCLA's Jonsson Comprehensive Cancer Center is involved in clinical trials testing new cancer drugs that treat discusses anti-PD1 and anti-PD-L1 drugs treating non-small cell lung cancer. In this informative 10-minute video, Dr. Garon discusses the remarkable tumor response...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=628Fri, 05 Apr 2013 10:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=628Antoni Ribas, M.D. of UCLA's Jonsson Comprehensive Cancer Center is involved in trials testing new cancer drugs targeting the cell surface molecule called PD-L1 and the immune cell receptors PD1. Early data from these trials involving non-small cell lung cancer, renal cancer and melanoma have...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=626Mon, 25 Mar 2013 13:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=626In an exciting breakthrough, scientists at UCLA’s Jonsson Comprehensive Cancer Center recently reported an encouraging increase in progression-free survival (or PFS, the length of time a patient is on treatment without tumor growth) for patients with HER2-negative breast cancer, a...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=624Tue, 22 Jan 2013 12:30:00 -0800http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=624Since 1987, the Glenn T. Seaborg Medal has been given to honor scientists for their contributions to chemistry and biochemistry. On December 7, 2012, the UCLA Department of Chemistry and Biochemistry awarded the 2012 Glenn T. Seaborg Medal to Harold Varmus, M.D., Director of the National Cancer...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=620Tue, 18 Dec 2012 10:30:00 -0800http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=620Researchers from the Revlon/UCLA Women’s Cancer Research Program at UCLA’s Jonsson Comprehensive Cancer Center (JCCC) reported an encouraging increase in progression-free survival (PFS, or the length of time a patient is on treatment without tumor growth) for patients with breast cancer that was...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=622Mon, 10 Dec 2012 10:30:00 -0800http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=622Matt Ferguson was inspired to start Matt's Chemo Bags during his freshman year of high school after finding out his mom had been diagnosed with invasive breast cancer. Motivated by the community's positive feedback to his cause, Ferguson expanded his breast cancer fundraising efforts and created a...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=618Mon, 03 Dec 2012 10:30:00 -0800http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=618Jennifer Marquez (with husband Christian and daughter Mckenzie)Jennifer Marquez has survived not one but two bouts with cancer. Her first diagnosis and treatment for thyroid cancer went smoothly enough. It was the second diagnosis with a rare form of sarcoma that presented a...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=616Mon, 05 Nov 2012 11:00:00 -0800http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=616Dr. Linda BaumResearchers at UCLA’s Jonsson Comprehensive Cancer Center have discovered the mechanism by which an experimental drug, GCS-100, removes a protein from lymphoma cells that prevents the cells from responding to chemotherapy. This discovery revives hope in GCS-100, a drug...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=614Fri, 12 Oct 2012 14:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=614In this 13-minute interview, Dr. Antoni Ribas of UCLA's Jonsson Comprehensive Cancer Center provides an overview of the latest positive advancements in the use of combination BRAF and MEK inhibition to treat metastic melanoma. These latest findings suggest strong support for testing the...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=612Fri, 05 Oct 2012 11:30:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=612UCLA's Jonsson Comprehensive Cancer Center completed a five-week interventional study of women recently treated for breast cancer who are experiencing cognitive difficulties commonly referred to as "chemo brain." In this CBS News segment, participant Diana Franklin of Los Angeles, who underwent...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=610Fri, 14 Sep 2012 12:15:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=610UCLA scientists have shown that two common tumor suppressor genes, TSC and PTEN, are vital to regulating the stem cell-like precursor cells that create the blood supply in Drosophila, the common fruit fly. The researchers examined a signaling pathway called TOR that the cells use to gauge...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=608Wed, 05 Sep 2012 14:30:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=608Patients with advanced kidney cancer are being sought to volunteer for a Phase I clinical trial at UCLA testing a novel kidney cancer vaccine that was developed based on pre-clinical laboratory and basic research done at UCLA’s Jonsson Comprehensive Cancer Center. The vaccine targets a marker that...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=606Mon, 27 Aug 2012 12:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=606Combining the recently approved BRAF inhibitor Zelboraf with an engineered T cell immunotherapy to treat metastatic melanoma significantly increased tumor responses and survival in an animal model, researchers at UCLA’s Jonsson Comprehensive Cancer Center have shown. The animals in the study that...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=604Wed, 15 Aug 2012 12:45:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=604Women recently treated for breast cancer who are experiencing cognitive difficulties commonly referred to as “chemo brain” are being sought to volunteer for an interventional study at UCLA’s Jonsson Comprehensive Cancer Center. The randomized study seeks to evaluate a five-week targeted...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=602Wed, 08 Aug 2012 12:15:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=602Dr. Beate RitzIn a large epidemiologic study, researchers at UCLA’s Jonsson Cancer Center found that the children of U.S.-born Latina women are at higher risk of having retinoblastoma, a malignant tumor of the retina which typically occurs in children under six. The study, which...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=600Mon, 06 Aug 2012 12:30:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=600Four Los Angeles business and community leaders joined the board of directors for the Jonsson Cancer Center Foundation, the fundraising arm of UCLA’s Jonsson Comprehensive Cancer Center. Alan Berro Mary Anne Keshen Linda Miller Savitt Clare SuomiAlan N. Berro is senior...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=598Wed, 18 Jul 2012 09:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=598UCLA’s Jonsson Comprehensive Cancer Center ranks among the top 10 cancer centers in the nation and is rated the best in California, according to a U.S. News & World Report survey of board-certified physicians from across the country. The survey reviewed patient outcomes, the cancer center’s...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=596Tue, 17 Jul 2012 11:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=596Compared to normal cells, cancer cells have a prodigious appetite for glucose, the result of a shift in cell metabolism known as aerobic glycolysis or the "Warburg effect." Researchers focusing on this effect as a possible target for cancer therapies have examined how biochemical signals present in...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=594Wed, 11 Jul 2012 10:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=594Religious and spiritual leaders help their congregants through many of life’s most difficult moments—death, divorce, lost jobs, crises of faith. But what is the right thing to do when one of their own has been diagnosed with cancer? What are the best ways to help the patient and their family through...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=592Fri, 29 Jun 2012 11:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=592During formation of multi-cellular organisms, cells need to talk to each other to make critical decisions as to what kind of cell to become, as well as when and where to become that cell type. The Notch signaling system allows cells to directly talk to each other to program almost every cell type in...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=590Thu, 31 May 2012 09:15:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=590During formation of multi-cellular organisms, cells need to talk to each other to make critical decisions as to what kind of cell to become, as well as when and where to become that cell type. The Notch signaling system allows cells to directly talk to each other to program almost every cell type in...http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=588Thu, 31 May 2012 09:00:00 -0700http://www.cancer.ucla.edu//Index.aspx?page=644&recordid=588